financetom
Business
financetom
/
Business
/
Dow's Post-Earnings Rally May Fade Amid Soft Market Demand, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dow's Post-Earnings Rally May Fade Amid Soft Market Demand, RBC Says
Oct 24, 2025 8:31 AM

11:12 AM EDT, 10/24/2025 (MT Newswires) -- Dow (DOW) shares surged after better-than-expected Q3 earnings before interest, taxes, depreciation and amortization and Q4 Ebitda guidance, but the rally may prove temporary given continued weak demand in consumer, building and construction, and industrial markets, RBC Capital Markets said in a note emailed Friday.

The analysts said that during the company's earnings call, Chief Executive Jim Fitterling highlighted ongoing challenges, including trade uncertainty, rising natural gas liquid costs, and weak global demand. He noted that while Dow sees long-term growth opportunities in its planned $6 to $7 billion net-zero Alberta cracker project, the initiative remains on hold pending better market conditions.

Fitterling added that in the near term, Dow expects a slight margin decline in the Packaging & Specialty Plastics, or P&SP, segment due to higher feedstock costs, although Q3 margins in both P&SP and Industrial Intermediates & Infrastructure improved thanks to new production capacity coming online, the analysts said.

The analysts raised their Ebitda forecasts to $725 million for Q4, $3.24 billion for full-year 2025, and $3.70 billion for 2026, from $678 million, $3.05 billion, and $3.45 billion, respectively, primarily due to the Q3 beat and Q4 guide and cost reductions. They added that they "remain cautious on Dow and other commodity names, as we are not seeing any material demand improvement in Consumer, B&C, or Industrial end markets."

RBC raised its price target on Dow to $27 from $24 and kept its sector perform rating.

Price: 24.51, Change: -0.01, Percent Change: -0.02

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sabio Signs Distribution Deal With Anoki, Gets Go-Ahead From TSXV for Stock Buyback
Sabio Signs Distribution Deal With Anoki, Gets Go-Ahead From TSXV for Stock Buyback
May 26, 2025
09:29 AM EDT, 05/20/2025 (MT Newswires) -- Sabio ( SABOF ) , a Los Angeles-based Adtech company, on Tuesday said it signed a distribution deal with Anoki to distribute the company's Creator Television (Creator TV) Free Ad-Supported Streaming Television (FAST) channel through LiveTVx, Anoki's AI-powered native FAST service on Google TV devices. In a separate press release, the company said...
BioNTech expands UK partnership with up to $1.33 billion investment
BioNTech expands UK partnership with up to $1.33 billion investment
May 26, 2025
May 20 (Reuters) - German vaccine maker BioNTech said on Tuesday that it plans to invest up to 1 billion pounds ($1.33 billion) over the next ten years to broaden its research and development activities in partnership with the UK government. The company said its subsidiary BioNTech UK signed a grant agreement with the UK government that builds on a...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Tempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment
Tempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment
May 26, 2025
09:26 AM EDT, 05/20/2025 (MT Newswires) -- Tempus AI ( TEM ) said Tuesday it is collaborating with Verastem ( VSTM ) to develop a companion diagnostic test for a combination treatment for recurrent low-grade serous ovarian cancer. Tempus said it completed confirmatory testing in Verastem's ( VSTM ) phase 2 clinical trial, which was the basis of the US...
Copyright 2023-2026 - www.financetom.com All Rights Reserved